| Species |
Human |
| Protein Construction |
IL-33 (Ser112-Thr270)
Accession # NP_254274.1 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-33, Human at 5μg/ml (100μl/well) on the plate can bind Human IL1RL1, His Tag. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
18 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 18 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-33 (IL-33) is a cytokine belonging to the IL-1 family, playing a role in inflammatory, infectious and autoimmune diseases and expressed in the cellular nucleus in several tissues. High levels of IL-33 are expressed in epithelial barrier tissues and endothelial barriers. ST2 is a receptor for IL-33, expressed selectively on a subset of Th2 cells, mediating some of their functions. |
| Synonyms |
C9orf26 Z; DVS27; IL1F11; NF-HEV; NFEHEV; IL33; DV27; C9ORF26; RP11-575C20.2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
